BenchSci vs Claude Science

Biopharma has used AI for years. What changed recently is agentic AI in the lab. The question has moved from whether to let it reason through real science to which platform should do it. You can build research on an AI platform purpose-built for drug discovery, or on a general-purpose AI platform from the same lab that sells you the model.

EMET by BenchSci and Claude Science are two of the names in that conversation. Both put powerful reasoning in front of scientists, both connect to scientific databases, and both can run analysis, read literature, and generate figures. Users can access Anthropic's frontier models on either platform, so if the comparison were only about the underlying models, this would be a short article.

But model quality was never the main question. What matters is everything a drug-discovery organization needs around the model: whether you are locked to one vendor, whether your AI partner also competes with you, what data it can actually reason over, how deeply it fits your workflow, and who shows up to make it work. These are the five criteria this article uses to evaluate EMET and Claude Science.

What to look for in AI for preclinical R&D

The gap between an impressive demo and a platform that actually moves preclinical research comes down to a handful of capabilities. Before comparing any two tools, it helps to define what separates a research environment built for drug discovery from a general-purpose AI platform pointed at science. Five things matter most.

• Freedom to use the best model for each task. The model frontier moves every few weeks, and no single model wins every scientific job. A tool tied to one lab's models ties your research to one vendor's roadmap, pricing, and availability.
• Aligned incentives and IP trust. In drug discovery, your AI partner should not also be a potential competitor. Whether the vendor develops drugs of its own is a core question, because your programs and your data are the most valuable things you own.
• Proprietary, science-specific data. A model is only as strong as the evidence it can reason over. Purpose-built biological data and structure will beat a general-purpose AI model with no privileged view into experimental biology, especially on the hard questions that decide a program.
• Depth of workflow and integration. Preclinical R&D is fragmented across thousands of data sources and hundreds of tools. Real value comes from a platform that fuses that ecosystem into the scientist's workflow, not one more capable silo sitting beside the others.
• A service model that drives adoption. Software alone does not change how an R&D organization works. Deployed expertise and workflows tailored to your teams are what turn a license into results, and what determine whether the platform is used a year later.

These capabilities rarely arrive together. A general-purpose AI platform tends to nail model access and flexible compute while leaving the data, the integration, and the adoption work to you. The sections below measure EMET and Claude Science against each criterion in turn.

Criterion 1: model flexibility and vendor independence

The model frontier is not standing still. A new best-in-class model can ship in any month, and no single model leads on every scientific task. The platforms that hold up are the ones that can always use the best available model as the frontier moves.

BenchSci is model-agnostic and routes every question to the best model for the task

EMET is model-agnostic by design. It owns no model of its own, which is exactly why it can route every question to the best available model instead of defaulting to one vendor's. Over 40 models are included today, spanning frontier and specialized systems.

Different models perform differently on different tasks. EMET selects the best model for each step, whether that is a frontier LLM, a specialized biomedical model such as ESM-2 or AbLang2, or a purpose-built tool, and it adopts each new frontier model as it ships.

The payoff for the buyer is future-proofing. When a stronger model ships, it becomes an upgrade rather than a migration. You are never captive to one lab's roadmap, one lab's pricing, or one lab's availability, and the best model always wins.

Claude Science runs on Anthropic's Claude models alone

Claude Science is, by design, a Claude-only reasoning environment. Anthropic has been refreshingly direct about this: the product runs the same Claude models already available to everyone today. Anthropic has said Claude Science is not a new model and not a more capable model for biology. It orchestrates some third-party specialized bio-models through NVIDIA's BioNeMo toolkit, but the reasoning engine at the center is Anthropic's own model family and nothing else.

That is a coherent design choice, and Claude's reasoning is genuinely strong. But the platform's ceiling is set by one vendor's model roadmap. If another lab ships a better model for a given task next month, Claude Science cannot switch to it. For an organization making a multi-year bet on its research infrastructure, that single-vendor dependence is a real risk.

Criterion 2: whether your AI partner also develops drugs

In drug discovery, the vendor relationship is unusually intimate. You are trusting an AI partner with your targets, your assays, and the programs that define your pipeline. The last thing you want is that partner to also become a competitor.

BenchSci does not develop drugs, and never will

BenchSci is a pure enablement partner. It builds the platform and stays on the tooling side of the line. It has committed never to discover its own drugs, which removes any conflict of interest. For a pharma company handing over its most sensitive IP, that neutrality is the clearest reason to trust the platform.

The payoff is alignment: BenchSci's only way to win is to make your scientists more effective.

Anthropic now runs its own drug-discovery program

This is no longer a hypothetical. On June 30, 2026, the same day it launched Claude Science, Anthropic announced its own drug-discovery program. The program is scoped to preclinical work on neglected and rare diseases, and Anthropic frames it as a way to sharpen Claude Science by developing drugs firsthand rather than as a commercial therapeutics business. Two months earlier, in April 2026, Anthropic made its first major acquisition, buying an AI drug-discovery biotech, and Novartis's CEO joined Anthropic's board around the same time. The longer-term ambition has been on record since Dario Amodei's 2024 essay, which describes using AI to "perform, direct, and improve upon nearly everything biologists do."

To be fair to Anthropic, it has not announced a clinical candidate or claimed it will bring a drug to market, and its stated motivation is tool credibility. But the direction is unambiguous and public. For a biopharma leader weighing where their IP will live, the question is simple: do you want your research environment built by a company that has publicly entered drug discovery itself, or by one that has committed never to?

Criterion 3: the data and evidence the platform reasons over

Both BenchSci and Claude Science can call a capable model, so the model is not where the key advantage lives. The advantage lives in the evidence a platform can reason over, and specifically whether that evidence is something everyone already has or something no one else can reach.

BenchSci reasons over a proprietary knowledge graph and closed-access science

A model is only as useful as the evidence beneath it, and this is where a decade of BenchSci's work compounds. EMET reasons over a proprietary Biological Evidence Knowledge Graph with 858M nodes and 2.2B relationship edges, described as the world's largest structured map of disease biology, layered with a proprietary ontological knowledge base. It draws on 38M+ scientific publications, including 16M closed-access papers reachable only through eight years of publisher partnerships with Elsevier, Springer Nature, Wiley, Oxford University Press, and dozens more. That corpus, plus the world's largest reagent and model-systems database, lives in EMET and nowhere else, every data point curated by a team of PhD scientists.

That structure is what lets EMET earn its answers rather than generate them. Its neuro-symbolic evaluation loop anchors generative output in the verified knowledge graph and delivers 95%+ accuracy on biological questions, two to four times better than frontier LLMs used alone, validated across 600+ tests and 8+ benchmarks. The payoff is answers grounded in real, cited experimental evidence rather than a model's general training.

Claude Science connects to public databases with no proprietary knowledge base

Claude Science ships with pre-configured access to 60+ scientific databases, including UniProt, PDB, Ensembl, Reactome, ClinVar, ChEMBL, and GEO, and it can connect to a lab's own data and compute. That connectivity is useful and well engineered. But it is general-purpose infrastructure: the platform reasons over public sources plus whatever you bring, with no proprietary, curated scientific knowledge graph of its own underneath it.

Public databases are available to everyone, so they confer no privileged advantage, and a general-purpose AI platform querying them still hits the wall on the science-specific questions that decide a program. Strong general reasoning cannot substitute for privileged, structured, expert-curated scientific data.

Criterion 4: workflow depth and ecosystem integration

Preclinical research does not happen in a chat window. It runs across dozens of databases, internal systems, and lab steps, and the value comes from a platform that fuses those into the scientist's actual workflow rather than adding one more tool beside it.

EMET is a biology-grounded platform built around preclinical workflows

Modern biology is fragmented across thousands of data sources and hundreds of tools, and scientists have become the connective tissue holding them together. EMET is built to close that gap.

It encodes 200+ proprietary scientific skills, organized into over 250 agents and workflows that carry a program across the full preclinical journey, from target identification and validation through hit discovery, lead optimization, safety and toxicology, translational biomarkers, and IND-enabling studies.

It also executes in the lab through lab-in-the-loop connectivity to automated infrastructure. The value comes from fusing these pieces around the scientist's workflow, which is what makes EMET a platform rather than a marketplace.

The advantage compounds. Each connector and each workflow makes the next one more valuable, so EMET fits how scientists already work and grows more useful over time rather than becoming one more thing to check.

Claude Science is a general-purpose platform that leaves the depth to you

Claude Science is a genuinely capable general research app. It manages compute across laptops, clusters, and cloud GPUs, runs persistent Python and R kernels, renders protein structures and genome tracks, and includes a reviewer agent that checks citations and calculations. These are strong, general-purpose research features.

Out of the box, Claude Science does not provide biology-grounded, preclinical workflows. It is a flexible surface, so building your specific target-validation or biomarker workflows is work that falls to you. In a fragmented stack, that risks adding one more silo instead of unifying them.

Criterion 5: deployment and service model

The best software still fails if no one adopts it. What determines whether a platform is still used a year later is rarely the interface; it is who shows up to tailor the platform to how each team actually works. The service model behind the product is the quiet deciding factor.

BenchSci deploys a dedicated scientific team that builds workflows for your organization

Software alone does not change how an R&D organization works, and BenchSci treats deployment accordingly. Every deployment includes a dedicated PhD team that understands your biology, your therapeutic areas, and your workflows.

They run training, manage change, and build bespoke connectors and workflows tailored to how your teams actually work. This is a scientific partnership rather than a support desk, and it is why customers build their research programs around EMET.

The payoff is real adoption and faster time to value. Workflows are built around the organization, so the platform actually gets used instead of sitting idle after rollout.

Claude Science is a self-serve app supported by third-party consultants

Claude Science is a downloadable desktop application, available to Claude Pro, Max, Team, and Enterprise subscribers, that runs on the lab's own infrastructure. For adoption at scale, Anthropic leans on implementation partners such as Accenture, Deloitte, KPMG, and PwC rather than an embedded scientific team. Much of the offering is also packaged for academic and nonprofit institutions, including thousands of free and discounted seats for researchers.

Self-serve is a strength for individual exploration, and running on your own infrastructure is a real privacy benefit. But it puts the burden of adoption, tailoring, and science-specific workflow design on the customer. A general consultancy can help roll out software; it is not the same as PhD scientists who understand your therapeutic area building your workflows alongside your bench.

Which AI belongs in your lab

This was never a debate about model quality. EMET and Claude Science sit on the same frontier of reasoning, and both are impressive in a demo. The difference is everything a drug-discovery organization actually needs around the model, and on each of the five criteria that matter for preclinical R&D, BenchSci is the stronger choice.

Claude Science is a capable general-purpose AI platform. EMET by BenchSci is a purpose-built research environment for biopharma R&D: model-agnostic, grounded in biology, and backed by scientists. If you are deciding where your programs and your data will live for the next several years, that is the difference that lasts.

See what EMET can do on your own targets. Book a demo with the BenchSci team.